Clinical Trials Browser

Phase 3 × Ondansetron × Other solid neoplasm × Clear all

NCT06208917 2024-01-17

Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children

Phase 3 Recruiting

Other solid neoplasm

Pediatric Solid Tumor, Unspecified, Protocol Specific